209 related articles for article (PubMed ID: 34861126)
1. Iron-based phosphorus chelator: Risk of iron deposition and action on bone metabolism in uremic rats.
Carmo WBD; Castro BBA; Manso LC; Carmo PAVD; Rodrigues CA; Custódio MR; Jorgetti V; Sanders-Pinheiro H
Exp Biol Med (Maywood); 2022 Mar; 247(5):446-452. PubMed ID: 34861126
[TBL] [Abstract][Full Text] [Related]
2. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
[TBL] [Abstract][Full Text] [Related]
3. Chitosan-Fe (III) Complex as a Phosphate Chelator in Uraemic Rats: A Novel Treatment Option.
do Carmo WB; Castro BBA; Rodrigues CA; Custódio MR; Sanders-Pinheiro H
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):120-125. PubMed ID: 28727296
[TBL] [Abstract][Full Text] [Related]
4. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
5. The Importance of Phosphate Control in Chronic Kidney Disease.
Tsuchiya K; Akihisa T
Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
[TBL] [Abstract][Full Text] [Related]
6. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
8. Digital radiography as an alternative method in the evaluation of bone density in uremic rats.
Castro BBA; Carmo WB; Oliveira RSMF; Peters VM; Jorgetti V; Custodio MR; Sanders-Pinheiro H
J Bras Nefrol; 2020 Mar; 42(1):8-17. PubMed ID: 31419270
[TBL] [Abstract][Full Text] [Related]
9. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
[TBL] [Abstract][Full Text] [Related]
13. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
14. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
Kusano K; Saito H; Segawa H; Fukushima N; Miyamoto K
J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
[TBL] [Abstract][Full Text] [Related]
15. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
17. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
18. Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease.
Jiang J; Li Y; Zheng D; Wang Z; Zhou H; Liu G
Int J Mol Med; 2020 Nov; 46(5):1783-1793. PubMed ID: 32901861
[TBL] [Abstract][Full Text] [Related]
19. Chitosan iron(III) reduces phosphorus levels in alloxan diabetes-induced rats with signs of renal failure development.
Schöninger LM; Dall'Oglio RC; Sandri S; Rodrigues CA; Bürger C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):467-71. PubMed ID: 20070292
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
